
Cyclosporine thumbs up for DED
One-year study results from the phase 3 Essence-2 open-label extension (OLE) study for cyclosporine ophthalmic solution 0.1% (Vevye) have shown sustained safety and efficacy in treating the signs and symptoms of dry eye disease (DED).












